Medpace Holdings, Inc. (MEDP) AI Stock Analysis

Medpace Holdings, Inc. specializes in providing comprehensive clinical research services for the development of pharmaceuticals and medical devices across North America, Europe, and Asia. Operating since 1992, the company provides a full spectrum of services spanning Phase I through Phase IV clinical trials for pharmaceutical, biotechnology, and medical device clients. Its services include strategic development planning, centralized laboratory services, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance, and post-marketing support. Headquartered in Cincinnati, Ohio, Medpace also operates bio-analytical laboratories, imaging services, electrocardiography reading capabilities, and human pharmacology clinics.

Medpace grew revenue from $1.14B in FY2021 to $2.53B in FY2025, recording a 5-year revenue CAGR of 22.3%. During this period, net income increased from $181.8M in FY2021 to $451.1M in FY2025, while EPS climbed from $4.91 to $15.30. Operating margin improved from 17.4% in FY2021 to 21.1% in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue grew 17.2% year-over-year, while quarterly earnings expanded 37.1% year-over-year. Trailing twelve month revenue reached $2.78B with an operating margin of 20.8% and EPS of $17.03.

As of June 30, 2026, Medpace held $502.7M in cash and short-term investments against total debt of $144.1M, yielding net cash of $358.6M. Shareholders' equity was $433.9M, with total assets of $2.06B, a current ratio of 0.73, and a debt-to-equity ratio of 0.33. In FY2025, the company generated $713.2M in operating cash flow, invested $31.4M in capital expenditures, and spent $917.4M on share buybacks, which contributed to a 5-year share count change of -23.8%.

Medpace has a market capitalization of $17.26B and an enterprise value of $16.84B. The stock trades at a trailing P/E of 36.3x and a forward P/E of 31.9x, both at a premium to the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its enterprise value-to-EBITDA stands at 27.6x, compared to the peer median of 12.0x, while its price-to-sales is 6.2x versus 4.1x for peers. Over the past 1 year, MEDP gained 18.7%, outpacing the S&P 500 (SPY) return of 16.8%, and delivered a 5-year return of 230.6% versus 83.0% for SPY.

Analyst ratings stand at 1 Strong Buy, 1 Buy, 11 Hold, 0 Sell, and 1 Strong Sell. The mean price target is $595.92, representing a 3.6% discount to the last close of $618.47. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $2.85B and EPS of $17.72, reflecting 15.9% EPS growth. Medpace has recorded 4 EPS beats over the last 4 quarters, and its next earnings date is October 21, 2026.

This page is an AI-written research summary of Medpace Holdings, Inc. (MEDP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MEDP income statement, MEDP balance sheet, MEDP key metrics, MEDP analyst forecast, MEDP chart. See the MEDP stock overview for the latest quote and news.